Abstract:Background: Rifampicin (rifampin) has been reported to have drug-drug interaction with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors due to its ability to influence the function of cytochrome P450 enzymes or transporters. Rosuvastatin is absorbed from the blood into the liver by organic anion transporting polypeptide 1B1 and is then metabolized by cytochrome P450 isozyme 2C9.Objective: The aim of this study was to examine the effect of rifampicin on the pharmacokinetics of rosuvastatin.Methods: This was a randomized, single-blind, placebo-controlled, crossover study, with a 4-week wash-out period. Healthy male volunteers were treated for 6 days with rifampicin 450 mg or placebo once daily. On days 0 and 7, a single oral dose of rosuvastatin 20 mg was administered. Plasma concentrations of rosuvastatin were measured by liquid chromatography-tandem mass spectrometry.Results: A total of 18 healthy Chinese male volunteers (mean [SD] age, 21 [2] years; weight, 62 [7] kg; and body mass index was within the normal range [22.0-24.0 kg/m(2)]) were included in the study. The plasma concentrations of rosuvastatin were not significantly changed by pretreatment with rifampicin, although there was considerable interindividual variation in the plasma concentration of rosuvastatin. During the rifampicin phase, the AUC(0-infinity) of rosuvastatin decreased in 10 and increased in 8 of the 18 subjects. In 3 of the 8 subjects, the AUC(0-infinity) of rosuvastatin during the rifampicin phase was >= 50% compared with the placebo phase; and only I increased by more than double (183%). Of those in the decreased group (n = 10), the AUC(0-infinity) values were decreased by > 50% In 3 subjects and were not decreased by > 30% in the remaining 7 subjects. The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL.h(-1)) of the corresponding value during the placebo phase (P = NS). There was no statistically significant difference in either C-max or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h). The oral clearance of rosuvastatin was not significantly affected by rifarnpicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).Conclusion: The pharmacokinetics of rosuvastatin were not significantly changed by coadministration of rifampicin in this small group of healthy male volunteers.

Food Effects on the Pharmacokinetics of Rosuvastatin Calcium Tablet After Administration of a Single Oral Dose in Healthy Chinese Subjects

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies

Pharmacokinetics and Bioequivalence of Two Formulations of Rosuvastatin Following Single‐dose Administration in Healthy Chinese Subjects Under Fasted and Fed Conditions

Pharmacokinetics of Multiple Oral Doses of Rosuvastatin Calcium Tablets

Pharmacokinetics of rosuvastatin calcium tablets in Chinese healthy volunteers after a single oral dose administration

Effect of Food on the Pharmacokinetics of Rosuvastatin after Administration of a Single Oral Dose in Dogs

The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion‐transporting Polypeptide 1B1

Effect of food on the single-dose pharmacokinetics and tolerability of clinofibrate tablets in Chinese healthy volunteers.

Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.

Effects of Food on Absorption of Ozagrel after Oral Administration in Healthy Volunteers

The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed‐Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects

Pharmacokinetics of Rosuvastatin when Coadministered with Rifampicin in Healthy Males: A Randomized, Single-Blind, Placebo-Controlled, Crossover Study

Comparison of efficacy of rosuvastatin and artovastatin in treatment of hypercholesterolemia

Pharmacokinetics and Food Effect of Enalapril Maleate/Folic Acid Tablets in Healthy Chinese Volunteers: A Phase I, Randomized, Open-label, Single- and Multiple-dose Study

An Accurate, Rapid and Sensitive LC-MS-MS Method for Quantification of Rosuvastatin in Human Plasma: Application to a Bioequivalence Study

The Effects of Food on the Bioavailability of Fenofibrate Administered Orally in Healthy Volunteers via Sustained-Release Capsule

Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers

The Efficacy and Safety of Rosuvastatin Calcium Tablets for Treatment of Hyperlipidemia

Effect of Ursolic Acid on Pharmacokinetics of Rosuvastatin in Rats

Study of Pharmacokinetics and Bioequivalence of Rosuvastatin Capsules by High Performance Liquid Chromatographic-Mass Spectrometry